Nicole S White, the Chief Manufacturing Officer of Assembly Biosciences (NASDAQ: ASMB), sold a small parcel of company stock and received a substantial restricted stock unit grant in late March 2026.
On March 30, 2026, White sold 197 shares of Assembly Biosciences common stock to satisfy tax withholding obligations. The block of shares traded at prices between $26.6502 and $27.49, producing total proceeds of $5,257. The sale was explicitly described as covering tax withholding.
The stock price at the time of reporting stands at $27.75. According to InvestingPro data, the share price has climbed 179% over the past 12 months. InvestingPro's analysis further indicates that, despite the recent appreciation, the stock remains undervalued relative to its Fair Value estimate.
These sales followed a grant made the previous day. On March 29, 2026, White was awarded 26,000 restricted stock units (RSUs) at no cost. The RSUs are scheduled to vest in four equal installments, subject to continuous service, on March 29 of each year from 2027 through 2030. After accounting for both the sale and the RSU grant, White is recorded as directly owning 37,477 shares of Assembly Biosciences.
Market commentators remain generally optimistic about the company. Analysts maintain bullish outlooks with price targets spanning from $39 to $62.
Below are the principal transaction details and contextual data disclosed by the company and reported via market data services.
- Insider sale: 197 shares sold on March 30, 2026 for $5,257 total, at prices between $26.6502 and $27.49; sale cited as covering tax withholding obligations.
- RSU grant: 26,000 restricted stock units granted on March 29, 2026 at no cost, vesting in four equal annual installments on March 29 of 2027, 2028, 2029, and 2030, contingent on continuous service.
- Ownership after transactions: White directly owns 37,477 shares.
- Share performance and valuation notes: Stock trades at $27.75 and is reported to have gained 179% over the last year; InvestingPro indicates the stock is still undervalued relative to Fair Value. Analyst price targets range from $39 to $62.
The record is limited to the company insider sale, the RSU grant and vesting schedule, the current share price and historical 12‑month performance metric, InvestingPro's valuation note, and the analysts' price targets. No further motives, additional compensatory details, or causal factors were disclosed in the reporting.